PROSYS ACT 10

Prodizen Inc

South Korea

Prodizen pionnered the development of PRP in South Korea, effectivelt introducing PRP therapy to the nation. With CE and U.S. FDA certifications, along with domestic and international license, Prodizen has amassed extensive expertise in cellular therapy. As a result of our relentless efforts, we have successfully facilitated the advancement of New Health Technology Assessment in orthopedics, ophthalmology, and obstetrics and gynecology, ultimately enabling the application of cell therapy across diverse fields. In 2023, we launched the BMC-S30 bone marrow concentrate kit from years of our expertise experience in cell therapy, Designed to streamline and expedite cell concentration processes, this kit provides safe and quick treatments to many patients. Prodizen is dedicated to conducting research and development across various fields to enable more people to receive cell therapy easily and quickly. We are committed to becoming a global leader in the cell therapy industry, extending our efforts beyond South Korea to benefit patients worldwide.